| Name | Title | Contact Details |
|---|---|---|
Sophie Mukadam |
Chief Operating Officer | Profile |
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
Custom Biogenic Systems is a Romeo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.
ARLG addresses antibacterial resistance through innovative clinical trial design, unique access to clinically well-characterized bacteria, and opportunities for early-stage investigators.
Surface Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicine and drugs for dry eye diseases. Surface Pharmaceuticals serves customers in the State of California.